**Obtain informed consent prior to tecovirimat initiation**

Expanded Access IND Protocol: Use of Tecovirimat (TPOXX®) for Treatment of Human Non-Variola Orthopoxvirus Infections in Adults and Children

IND No. 116,039

CDC IRB No. 6402

Version 6.3
May 5, 2023

Sponsored by:

Centers for Disease Control and Prevention

In Collaboration with:
Biomedical Advanced Research and Development Authority
Office of the Assistant Secretary for Preparedness and Response
Department of Health and Human Services

This expanded access IND protocol for tecovirimat is held by the Centers for Disease Control and Prevention. Unauthorized reproduction or misuse beyond the intended purpose of the protocol is prohibited.
PROGRAM CONTACT INFORMATION

Coordinating Program:
Poxvirus and Rabies Branch
Division of High-Consequence Pathogens and Pathology (DHCPP)
National Center for Emerging and Zoonotic Infectious Diseases (NCEZID)
1600 Clifton Road, MS H24-12, Atlanta, GA 30329
Phone: (404) 639-4129
Email: poxvirus@cdc.gov

Clinical:

Sponsor Principal Investigator
Agam Rao, M.D., FIDSA
Poxvirus and Rabies Branch
DHCPP, NCEZID, CDC
1600 Clifton Road NE, MS H24-12, Atlanta, GA 30333
Email: poxvirus@cdc.gov

Regulatory:
Yon Yu, Pharm.D.
Lead, Regulatory Affairs and Clinical Guidelines Team
Emergency Preparedness and Response Branch,
Division of Preparedness and Emerging Infections, NCEZID, CDC
1600 Clifton Road NE, MS H24-11, Atlanta, GA 30333
Email: regaffairs@cdc.gov

CDC Emergency Operation Center: (770) 488-7100
# TABLE OF CONTENTS

1.0 INTRODUCTION AND BACKGROUND ........................................................................................................... 3
  1.1 Unmet Medical Need and Rationale for Use of Tecovirimat under Expanded Access IND ............. 4
2.0 PROGRAM OBJECTIVE ........................................................................................................................................ 4
  2.1 Tecovirimat Eligibility ..................................................................................................................................... 4
  2.2 Tecovirimat Ineligibility ................................................................................................................................. 7
3.0 PRODUCT DESCRIPTION .................................................................................................................................... 7
  3.1 Tecovirimat Formulations ............................................................................................................................... 7
4.0 DOSAGE AND ADMINISTRATION OF TECOVIRIMAT .............................................................................. 8
  4.1 Oral Therapy for Adults and Children ......................................................................................................... 8
  4.2 IV Therapy for Adults and Children ............................................................................................................ 10
  4.4 Discontinuation of Tecovirimat .................................................................................................................... 11
  4.5 Drug-Drug Interactions ............................................................................................................................... 11
5.0 POSSIBLE RISKS OF TECOVIRIMAT TREATMENT ............................................................................. 12
6.0 SPECIAL POPULATIONS ............................................................................................................................. 12
  6.1 Pregnancy ..................................................................................................................................................... 12
  6.2 Lactation ..................................................................................................................................................... 13
  6.3 Pediatric Population ..................................................................................................................................... 13
  6.4 Patients with Renal Impairment ................................................................................................................ 13
7.0 CLINICAL ASSESSMENT AND MONITORING OF PATIENTS .................................................................. 13
  Optional Laboratory Testing ............................................................................................................................ 15
8.0 RECORDING AND REPORTING SERIOUS ADVERSE EVENTS ............................................................. 17
  8.1 Definitions (21 CFR 312.32) ........................................................................................................................ 17
  8.2 Treating Clinician Reporting Requirements to CDC ........................................................................... 17
  8.3 CDC Reporting Requirements to FDA and CDC Institutional Review Board (IRB) .................. 17
9.0 REGULATORY AND ADMINISTRATIVE REQUIREMENTS ..................................................................... 18
10.0 SUMMARY OF AVAILABLE SAFETY AND EFFICACY DATA OF TECOVIRIMAT ...................... 19
  10.1 Human Safety Data of Tecovirimat ......................................................................................................... 19
  10.2 Clinical Use of Tecovirimat in NV-OPXV-infected Patients (2007–2021) ........................................... 20
  10.3 Tecovirimat Efficacy in Animals ............................................................................................................ 22
  10.4 Pharmacokinetics Data ............................................................................................................................ 23
11.0 REFERENCES ................................................................................................................................................. 23

## ATTACHMENTS

Attachment 1: [Informed Consent/Parental Permission Form](#)

Attachment 2: Electronic TPOXX IND Treatment Forms:
  - Form A: Required Patient Intake Form
  - Form B: Clinical Outcome Form

Attachment 3: [Instructions for Opening and Mixing Tecovirimat Capsules with Water or Food for Those Who Cannot Swallow Pills, Especially Infants and Children](#)

Attachment 4: [Optional Lesion Specimens to CDC for Resistance Testing](#)

Attachment 5: [Optional Pharmacokinetic Sampling for Testing at Alturas Analytics](#)

Report serious adverse events and selected adverse events of interest by completing a fillable-PDF MedWatch Form and returning to CDC via email (regaffairs@cdc.gov) within 72 hours of occurrence or sooner (See Section 7.0).
1.0 INTRODUCTION AND BACKGROUND

Orthopoxviruses (OPXVs) belonging to the Poxviridae family that infect humans are variola virus (smallpox), vaccinia virus (the virus in smallpox vaccine ACAM2000 and smallpox/mpox vaccine Jynneos), monkeypox virus (MPXV), cowpox virus, Akhmeta virus and Alaskapox virus. Variola virus, the etiologic cause of smallpox, is the only one that affects humans exclusively, while the others are zoonotic infections that can also be transmitted person-to-person. Poxvirus infections may be localized to the skin or disseminated. The initial site of infection may be the skin, a mucosal surface, or the respiratory tract. Orthopoxviruses, such as mpox (previously known as monkeypox), can also cause serious clinical illness including, but not limited to encephalitis, severe inflammatory response syndrome, respiratory failure, painful head and neck lymph node swelling with or without associated airway and/or swallowing compromise, extensive dermal disruption during rash phase, and/or other septic syndromes.

Since the worldwide eradication of smallpox, the other orthopoxviruses or non-variola orthopoxvirus (NV-OPXV) infections are emerging as a growing public health concern given the potential for spread through international travel, especially among populations that have not been previously vaccinated, and delayed recognition of NV-OPXV infections by healthcare professional who may be less familiar with these infections. There are two genetic clades of MPXV: Clade I and Clade II, which have been historically found in central and west Africa, respectively, with only Cameroon reporting both clades [1]. Recent cases of human mpox in countries outside of west and central Africa underscore the risk of spread of MPXV from beyond its normal endemic region and the potential for sustained local transmission. In 2003, a mpox outbreak occurred in the United States (U.S.) through direct or indirect contact with MPXV-infected prairie dogs, where 47 confirmed or probable cases of human mpox were identified: 37% of cases were hospitalized, although illness severity was usually mild. Two patients were hospitalized with severe disease; there were no deaths reported. To prevent transmission of mpox, a replication-competent smallpox vaccine (Dryvax®, which is no longer available) was administered to 30 individuals (pre-exposure to 7 and post-exposure to 23) with no reported serious adverse events following smallpox vaccination.

During September 2018–May 2021, seven unrelated persons traveling from Nigeria received diagnoses of mpox in non-African countries: five in the United Kingdom and one each in Israel and Singapore [4-6]. Response to the cases in United Kingdom included offering vaccination with Imvanex (marketed as Jynneos® in the U.S.) as post-exposure prophylaxis (PEP) and antiviral treatment in 3 mpox-infected individuals (1 received tecovirimat; 2 received brincidofovir). In July and November 2021, two independent cases of mpox in travelers from Nigeria were diagnosed in Texas and Maryland and one patient was treated with tecovirimat [7, 8].

A global outbreak of mpox cases (Clade Iib) reported in European countries and the U.S starting in May 2022 led to the World Health Organization declaring the outbreak to be a public health emergency of international concern in July 2022 [9, 10], and over 86,000 mpox cases in over 100 countries have occurred during the outbreak [9]. Mpx was also declared as a national public health emergency (PHE) on August 2, 2022 in the U.S., activating public health response efforts to control the spread of transmission with enhanced surveillance activities, expansion of laboratory testing, deployment of stockpiled vaccines for prevention of mpox and therapeutics for treatment, clinical guidance to providers and information for the public. With sustained low number of mpox cases, continued close monitoring of case trends, and vaccination for the at-risk individuals, the mpox PHE ended on January 31, 2023. During the mpox outbreak in the U.S., over 30,200 cases and 38 deaths have been reported as of mid-March 2023 [11]. The majority of reported cases during the outbreak were men who identify as gay, bisexual or men who have sex with other men while anyone, regardless of sexual orientation or gender identity, who has been in close contact with someone with mpox is at risk [12]. Vaccination is the key modality for prevention of orthopoxvirus (OPXV) infections. There are two vaccines approved by the Food and Drug Administration (FDA) for OPXV infections - ACAM2000 (replication-competent, live vaccinia vaccine approved for
smallpox for adults and children) and Jynneos (replication-deficient, Modified Vaccinia Ankara-Bavarian Nordic [MVA-BN] approved for smallpox and mpox in adults 18 years and older). However, vaccination must occur either before or soon after exposure to be effective in preventing or reducing the seriousness of the disease caused by orthopoxvirus infections. During an outbreak, effective therapeutic options also are necessary. Additionally, with widespread vaccination, vaccinia vaccine-related complications may occur that necessitate treatment options.

1.1 Unmet Medical Need and Rationale for Use of Tecovirimat under Expanded Access IND
Currently, there is no treatment approved by the Food and Drug Administration (FDA) for non-variola orthopoxvirus, including MPXV. Although tecovirimat is FDA-approved for treatment of smallpox in adults and children, the approved indication is limited to smallpox. Therefore, this intermediate-size patient population expanded access Investigational New Drug (IND), sponsored by the Centers for Disease Control and Prevention (CDC) and authorized by FDA, is to allow access to and use of stockpiled tecovirimat for treatment of non-variola orthopoxvirus (NV-OPXV) infection in adults and children.

While the effectiveness of tecovirimat in treating human non-variola orthopoxvirus infections, including mpox, has not been evaluated, it may be reasonable to anticipate potential treatment benefit based on animal efficacy data that supported FDA-approval for smallpox treatment and clinical uses of tecovirimat in the treatment of NV-OPXV infected individuals to date. During the 2022 mpox outbreak response in the U.S., tecovirimat was prescribed or administered in 6,832 patients for mpox [13] (see Section 10.2).

Tecovirimat has been shown to be effective against various orthopoxviruses in multiple animal challenge models [14, 15]. Tecovirimat was approved for smallpox under the FDA’s Animal Rule, which allows efficacy findings from adequate and well-controlled animal studies to support an FDA approval when it is not feasible or ethical to conduct efficacy trials in humans.

2.0 PROGRAM OBJECTIVE
The purpose of this expanded access IND (compassionate use) program is to provide stockpiled tecovirimat for treatment of non-variola orthopoxvirus infections (e.g., mpox, vaccinia, or other human virus infection identified as an orthopoxvirus) and secondary treatment of complications from replication-competent vaccinia virus vaccine in adults, pregnant or lactating individuals, and children, who meet eligibility for tecovirimat treatment under the IND. An expanded access IND regulatory mechanism is required for access to and unapproved uses of the stockpiled tecovirimat since the antiviral is FDA-approved only for treatment of smallpox based on animal efficacy data.

To monitor clinical use of tecovirimat under this expanded access IND program, occurrence of serious adverse events and/or selected adverse events of interest, patient treatment, and outcomes information are also intended to be collected under this expanded access IND program to the extent feasible (e.g., baseline clinical conditions, progression/improvement during or post treatment, recovered or not recovered from orthopoxvirus infection). Please refer to Section 7.0 Clinical Assessment and Monitoring of Patients.

2.1 Tecovirimat Eligibility
As tecovirimat is not FDA-approved for the treatment of mpox, a randomized controlled clinical trial called STOMP (Study of Tecovirimat for Human Mpox Virus) is actively recruiting and enrolling patients with mpox to evaluate the efficacy and safety of tecovirimat for mpox. Oral tecovirimat treatment for mpox is available through STOMP. Providers should inform patients about STOMP for their consideration of voluntary enrollment in this study. Use of tecovirimat under this EA-IND protocol should be for patients who declare voluntary participation in STOMP, are ineligible for STOMP (e.g., prior tecovirimat treatment, illness duration > 14 days), or require IV tecovirimat treatment. Since efficacy of tecovirimat has not been evaluated in clinical studies in orthopoxvirus-infected patients,
maximizing the opportunity for clinical study when mpox cases occur or are ongoing is of public health importance to help inform evidence-based guidance, clinical and strategic decisions.

Only patients, who meet eligibility criteria noted below, can receive tecovirimat treatment under this IND program. Eligibility criteria for tecovirimat therapy during an outbreak may evolve depending on the duration and nature of the outbreak and event-based information that may become available during the outbreak. Tecovirimat use allowed under this IND protocol is in concert with CDC’s guidance for clinical management and treatment of poxvirus diseases. For more information, please refer to CDC websites at: Poxvirus | CDC, Treatment Information for Healthcare Professionals | Mpox | Poxvirus | CDC, Guidance for Tecovirimat Use | Mpox | Poxvirus | CDC, and Interim Clinical Treatment Considerations for Severe Manifestations of Mpox — United States, February 2023 | MMWR.

2.1.1 Primary or early empiric treatment

- **Mpox**
  Patients who have the following clinical manifestations may receive tecovirimat treatment under this EA-IND protocol:
  
  - Severe disease — consider severe disease when a patient has conditions such as hemorrhagic disease; a large number of lesions such that they are confluent; necrotic lesions; severe lymphadenopathy that can be necrotizing or obstructing (such as in airways); involvement of multiple organ systems and associated comorbidities (for example, pulmonary involvement with nodular lesions; sepsis; encephalitis; myocarditis; ocular or periorbital infections); or other conditions requiring hospitalization.
  
  - Involvement of anatomic areas which might result in serious sequelae that include scarring or strictures — these include lesions directly involving the pharynx causing dysphagia, inability to control secretions, or need for parenteral feeding; penile foreskin, vulva, vagina, urethra, or anorectum with the potential for causing strictures or requiring catheterization; anorectal lesions interfering with bowel movements (for example, severe pain); and severe infections (including secondary bacterial skin infections), especially those that require surgical intervention such as debridement.

Patients who are at high risk for severe disease may receive tecovirimat treatment under this EA-IND protocol:

- People currently experiencing severe immunocompromise due to conditions such as advanced or poorly controlled human immunodeficiency virus (HIV), leukemia, lymphoma, generalized malignancy, solid organ transplantation, therapy with alkylating agents, antimitabolites, radiation, tumor necrosis factor inhibitors, high-dose corticosteroids, being a recipient of a hematopoietic stem cell transplant <24 months post-transplant or ≥24 months but with graft-versus-host disease or disease relapse, or having autoimmune disease with immunodeficiency as a clinical component

- Pediatric populations, particularly patients younger than 1 year of age

- Pregnant or breastfeeding people

- People with a condition affecting skin integrity — conditions such as atopic dermatitis, eczema, burns, impetigo, varicella zoster virus infection, herpes simplex virus infection, severe acne, severe diaper dermatitis with extensive areas of denuded skin, psoriasis, or Darier disease (keratosis follicularis)

For patients at high risk for progression to severe disease, treatment should be administered early in the course of illness along with supportive care and pain control.

- **Non-variola orthopoxvirus other than mpox**
  Tecovirimat treatment may be initiated for patients with laboratory confirmed non-variola orthopoxvirus infection or suspected infection based on known exposure(s) and clinical
manifestations of disease while laboratory confirmation may be pending. Patients with an initial negative OPXV test, but for whom both epidemiologic and clinical evidence suggests OPXV disease (particularly if clinical progression is worsening), should be re-tested but be treated with tecovirimat while results are pending. If results from re-testing confirm orthopoxvirus, patients should continue tecovirimat treatment. If results from re-testing confirm the initial negative orthopoxvirus results, tecovirimat should be suspended in those patients.

2.1.2 Secondary treatment of complications from replication-competent vaccinia virus vaccine
Patients with complications of replication-competent vaccinia virus infection (e.g., serious inadvertent inoculation with vaccinia, eczema vaccinatum, severe generalized vaccinia, or progressive vaccinia) resulting from vaccination with ACAM2000, secondary transmission, or other exposure from close contact with the vaccinee are eligible for treatment with tecovirimat. Tecovirimat may be used if a patient is ineligible for Vaccinia Immune Globulin Intravenous (VIGIV) treatment, after VIGIV treatment has been exhausted, or in conjunction with VIGIV and/or other therapies based on the treating clinician’s clinical judgment in consultation with CDC. For information on smallpox vaccine adverse events, see https://www.cdc.gov/smallpox/clinicians/vaccine-adverse-events5.html

2.1.3 Post-exposure prophylaxis (PEP)
Tecovirimat may be considered for post-exposure prophylaxis on an individual case-by-case basis in consultation with CDC (Emergency Operations Center [EOC] (770) 488-7100) depending on the known high-risk exposure to a confirmed or probable case of NV-OPXV infection (as defined on https://www.cdc.gov/poxvirus) and clinical conditions that necessitate an alternative or complementary option to PEP vaccination based on clinical judgment (e.g., severe allergic reaction to vaccine or vaccine components, immunocompromising conditions).

2.1.4 Considerations for IV tecovirimat
IV tecovirimat should be considered for adults and children who are unable to take oral therapy or for whom there is a concern that oral drug absorption may be altered. These include critically ill patients hospitalized and unable to feed sufficiently by mouth, as oral tecovirimat absorption is expected to be lower in these patients since bioavailability of oral tecovirimat is dependent on adequate intake of a full, fatty meal. Patients with gastric bypass or evidence of gastrointestinal dysfunction that may negatively impact drug absorption may also be considered for treatment with IV tecovirimat. IV tecovirimat has a labeled contraindication in patients with severe renal impairment (creatinine clearance [CrCl] < 30 mL/min) due to potential accumulating of hydroxypropyl-β-cyclodextrin (HP-β-CD), an excipient in the IV tecovirimat formulation which is eliminated through glomerular filtration. Therefore, enteral administration of oral tecovirimat should be exhausted in renally impaired patients, and IV tecovirimat should not be administered in patients with CrCl < 30 mL/min. Exceptions may be considered only if drug absorption via enteral administration is not anticipated to be dependable or feasible, and based on individual patient risk-benefit assessment by the treating clinician that determines IV tecovirimat clinically necessary in consultation with CDC. In these instances, IV tecovirimat use must be with caution and close continuous monitoring of renal function. See Section 2.2 Tecovirimat Ineligibility.

In the absence of an oral tecovirimat suspension formulation, IV tecovirimat may be considered for children weighing less than 13 kg based on clinical assessment of risk/benefit and if determined appropriate by the treating clinician. Opening the capsule and mixing the entire capsule contents with 20 mL of water to measure the right amount of drug-water mixture to give is an alternative option for younger children weighing less than 13 kg (see Table 4.1), which is allowed under the IND. However, oral doses less than a full capsule content (200 mg) require careful preparation by a caregiver and have the inherent potential for inaccurate dosing. Refer to Instructions for Opening and Mixing Tecovirimat Capsules with Water or Food for Those Who Cannot Swallow Pills, Especially Infants and Children (Attachment 3) for detailed preparation instructions.
Patients who receive IV tecovirimat should be switched to the oral tecovirimat capsules as soon as they are able to take oral medications and/or gastrointestinal dysfunction impacting absorption has resolved. The timing of transition to oral therapy is based on the clinical judgement of the treating clinician depending on the clinical progress of the patient.

2.2 Tecovirimat Ineligibility

- Patient or legally authorized representative unwilling to sign an informed consent and refuse tecovirimat treatment
- Known allergy to tecovirimat and/or inactive ingredients in tecovirimat
- For IV tecovirimat only: patients with severe renal impairment (CrCl <30 mL/min)*. Oral tecovirimat is an option for patients with severe renal impairment.

*Note: IV tecovirimat has a labeled contraindication in patients with CrCl < 30 mL/min. Exceptions may be considered only if drug absorption via enteral administration is not anticipated to be dependable or feasible, and based on individual patient risk-benefit assessment by the treating clinician that determines IV tecovirimat clinically necessary in consultation with CDC. In these instances, IV tecovirimat use must be with caution and close continuous monitoring of renal function.

3.0 PRODUCT DESCRIPTION

Tecovirimat (tecovirimat monohydrate) is an inhibitor of the orthopoxvirus VP37 envelope wrapping protein, which prevents the formation of egress-competent enveloped virions necessary for cell-to-cell and long-range dissemination of virus [16]. Depending upon the poxvirus species, its inhibitory activity is from 600- to several thousand-fold greater than that of cidofovir and other drugs used for treatment of orthopoxviruses. In cell culture assays, the effective concentrations of tecovirimat resulting in a 50% reduction in virus-induced cytopathic effect (EC50), were 0.016–0.067 μM, 0.014–0.039 μM, 0.015 μM, and 0.009 μM for variola, mpox, rabbitpox, and vaccinia viruses, respectively. There is no structural resemblance of tecovirimat to any other compound currently used in human therapeutics; therefore, no comparison or correlation can be made to human experience for any other known drug. Refer to tecovirimat Package Insert for additional details.

3.1 Tecovirimat Formulations

Tecovirimat is available as oral capsules and injection vials. Each capsule contains 200 mg of tecovirimat active ingredient and comes in unit of use bottle containing 42 capsules. All inactive ingredients/excipients are generally recognized as safe and are United States Pharmacopeia/National Formulary grade. The capsules include the following ingredients: colloidal silicon dioxide, croscarmellose sodium, hydroxypropyl methyl cellulose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and sodium lauryl sulfate. Tecovirimat capsules should be stored at room temperature at 20–25°C (68–77°F). Excursions are permitted to 15–30°C (59–86°F).

Tecovirimat injection (200 mg/20 mL) single-dose vial contains tecovirimat monohydrate (unmicronized) equivalent to 200 mg tecovirimat and the excipient HP-β-CD 8000 mg. The vial stopper is not made with natural rubber latex. Tecovirimat injection must be diluted with 2 parts 0.9% normal saline or 5% dextrose solution prior to infusion. Tecovirimat injection vials should be stored at 2–8°C (36–46°F). Do not freeze. Short-term storage of maximum 24 hours at ambient temperature is acceptable.

The immediate container/packaging of tecovirimat does not have a printed expiry date as expiry extensions may occur. To determine the expiration date, find the lot number on the product label and refer to the table on the following website to locate the corresponding expiration date: https://aspr.hhs.gov/sns/Pages/mpox.aspx. Refer to this website to check the expiry dates for both oral and IV tecovirimat by lot #s.
4.0 DOSAGE AND ADMINISTRATION OF TECOVIRIMAT
Tecovirimat dosing for adults and children are as shown in Table 1 (oral) and Table 2 (IV) for 14 days of therapy. In certain clinical situations, modifications to the dose, frequency, and duration may be necessary depending on the individual patient’s clinical condition, disease progression, therapeutic response, and/or clinical judgement in consultation with CDC and FDA as appropriate. To request clinical consultation regarding tecovirimat treatment, contact the CDC (EOC (770) 488-7100).

4.1 Oral Therapy for Adults and Children
Oral tecovirimat should be taken by mouth with a full glass of water within 30 minutes after eating a full meal of moderate or high fat (ideally about 600 calories and 25 grams of fat) in order to improve bioavailability.

<table>
<thead>
<tr>
<th>Weight (kg)</th>
<th>Weight (lbs)</th>
<th>Recommended Dose (mg)</th>
<th>Drug-Water or Drug-Food Preparation for Patients Who Cannot Swallow Capsules (see Attachment 3)be</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 3 kg</td>
<td>&lt; 7 lbs</td>
<td>33.3 mg every 12 hours</td>
<td>Carefully open 1 capsule and empty the entire contents into a dosing cup of suitable size. Add 20 mL of water to the dosing cup and thoroughly mix by swirling the cup for at least 30 seconds until there are no clumps. Do not use a spoon or any other utensil to mix. Immediately after mixing, use an oral syringe to draw up and administer 3.3 mL of the water and drug mixture. Discard the remaining mixture. Give this amount 2 times each day, making a new mixture for each dose. Note: Dosing should be followed by a feeding.</td>
</tr>
<tr>
<td>3 kg to &lt; 6 kg</td>
<td>7 lbs to &lt; 13 lbs</td>
<td>50 mg every 12 hours</td>
<td>Carefully open 1 capsule and empty the entire contents into a dosing cup of suitable size. Add 20 mL of water to the dosing cup and thoroughly mix by swirling the cup for at least 30 seconds until there are no clumps. Do not use a spoon or any other utensil to mix. Immediately after mixing, use an oral syringe to draw up and administer 5 mL of the water and drug mixture. Discard the remaining mixture. Give this amount 2 times each day, making a new mixture for each dose. Note: Dosing should be followed by a feeding.</td>
</tr>
<tr>
<td>6 kg to &lt; 13 kg</td>
<td>13 lbs to &lt; 28 lbs</td>
<td>100 mg every 12 hours</td>
<td>Carefully open 1 capsule and empty the entire contents into a dosing cup of suitable size. Add 20 mL of water to the dosing cup and thoroughly mix by swirling the cup for at least 30 seconds until there are no clumps. Do not use a spoon or any other utensil to mix. Immediately after mixing, use an oral syringe to...</td>
</tr>
</tbody>
</table>
draw up and administer 10 mL of the water and drug mixture, either directly or mixed in a small amount of soft food (e.g., apple sauce, yogurt). Discard the remaining mixture. Give this amount 2 times each day, making a new mixture for each dose.

Note: Dosing should be followed by a feeding.

<table>
<thead>
<tr>
<th>Weight Range</th>
<th>Dose</th>
<th>Frequency</th>
<th>Preparation and Administration</th>
</tr>
</thead>
<tbody>
<tr>
<td>13 kg to &lt; 25 kg</td>
<td>200 mg (1 capsule) every 12 hours</td>
<td>Carefully open the required number of capsules and mix contents of capsule(s) with 30 mL of liquid (e.g., milk, chocolate milk, water) or soft food (e.g., apple sauce, yogurt). Administer the entire mixture within 30 minutes of preparation.</td>
<td></td>
</tr>
<tr>
<td>25 kg to &lt; 40 kg</td>
<td>400 mg (2 capsules) every 12 hours</td>
<td></td>
<td></td>
</tr>
<tr>
<td>40 kg to &lt; 120 kg</td>
<td>600 mg (3 capsules) every 12 hours</td>
<td></td>
<td></td>
</tr>
<tr>
<td>120 kg and above</td>
<td>600 mg (3 capsules) every 8 hours</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*a For patients weighing ≥ 13 kg, tecovirimat capsules should be taken within 30 minutes after a full meal containing moderate or high fat. For pediatric patients weighing < 13 kg, tecovirimat dose should be followed by a feeding. The standard treatment duration is 14 days. Based on the risk-benefit assessment of individual patients and depending on the disease progression, tecovirimat treatment may be extended beyond 14 days or shortened due to lack of virologic or clinical response, or occurrence of adverse events. Data on duration other than 14 days are limited.

*b Opening tecovirimat capsules and mixing in water for children weighing < 13 kg, which differs from the FDA-approved tecovirimat package insert, is allowed under this IND protocol.

*c Use of water for oral dose preparation and administration is not in the FDA-approved labeling but is allowed under this IND protocol.

The adult dosing does not preclude pregnant or nursing individuals if careful clinical assessment of risk/benefit deems tecovirimat treatment appropriate per the treating clinician’s clinical judgement (see Section 6.0 for Special Populations). PK information is not available for pediatrics. The pediatric doses are solely based on predicted exposures from population PK simulation predicted to provide pediatric patients with exposures comparable to the observed exposure in healthy adult volunteers receiving oral 600 mg doses twice daily. Oral doses less than 200 mg require careful preparation by a caregiver (e.g., opening a capsule and mixing the capsule contents in water, then administering a portion of the drug-water preparation) and has the inherent potential for inaccurate dosing. Suboptimal dosing increases the potential for development of resistance. Tecovirimat absorption may likely be decreased and result in potential suboptimal exposure in ill children, particularly young children, who are unable or unwilling to take a full meal prior to tecovirimat administration. The potential for inaccurate dosing when opening capsules for doses below 200 mg may be higher in the outpatient setting.

4.1.1 Duration of Oral Therapy
The standard duration of tecovirimat treatment for patients of all ages is 14 days. Data on duration other than 14 days are limited. Potential adjustments to dose and/or duration of tecovirimat treatment may be necessary per individual clinical considerations. Based on the risk-benefit assessment of individual patients and depending on the disease progression, oral tecovirimat treatment may be extended beyond 14 days or shortened due to lack of virologic or clinical response and/or occurrence of adverse events. Tecovirimat treatment beyond the standard 14-day course may be considered at short increments of extension (e.g., an additional 3–7 days) at a time while monitoring for clinical improvement or lack of response and adverse events to reassess continuing or stopping tecovirimat treatment accordingly.

Tecovirimat resistance has been detected in a small number of patients with advanced HIV who received tecovirimat for durations of weeks to months [18-20, 28]. In the 3-month general toxicology studies with oral (gavage) tecovirimat in mice and monkeys, no adverse, drug-related findings were observed.
4.1.2 Patients who are Unable to Swallow Capsules
For children who require less than a 200 mg dose or adults who are unable to swallow capsules being treated as outpatients, treating clinicians should provide instructions on how to open capsules and mix in water or with food (Attachment 3). The dosing instructions for using less than 1 capsule (200 mg) have not been formally evaluated but are included to provide dosing options for younger age children, especially if IV tecovirimat is not available or feasible for administration.

For pediatric and adult inpatients unable to feed by mouth and with no evidence of gastrointestinal dysfunction, tecovirimat may be administered via a nasogastric tube (NGT) per hospital protocol based on clinical judgment of individual patients if IV tecovirimat is unavailable or IV infusion is not feasible (e.g., renally impaired patient, lack of syringe pumps). Although NGT administration is allowed under the IND to provide an alternative option in case of limited supply of IV tecovirimat or if infusion is not feasible, compatibility studies on enteral administration of tecovirimat have not been conducted.

4.2 IV Therapy for Adults and Children
Due to potential accumulation of HP-β-CD, an excipient in the IV tecovirimat formulation which is eliminated through glomerular filtration, FDA-approved package insert contraindicates IV tecovirimat in patients with CrCl <30 mL/min. Oral tecovirimat option should be exhausted, including enteral administration via NG tube. See Section 2.2 Tecovirimat Ineligibility.

Tecovirimat injection vials should be stored at 2-8°C (35-46°F). IV tecovirimat must be diluted prior to administration. See the Package Insert for additional details.

- Withdraw the volume of tecovirimat injection solution corresponding to the dose in Table 2. Add this volume to a suitable size syringe. Then dilute by adding 2 equal parts of either 0.9% normal saline or 5% dextrose solution to the syringe containing tecovirimat solution.
- Gently swirl the syringe of in-use solution prior to inserting into the syringe pump and infuse over 6 hours.
- The diluted IV tecovirimat should be administered immediately upon preparation and must be used within 24 hours of preparation if stored at 2-8°C (35-46°F).

<table>
<thead>
<tr>
<th>Weight (kg)</th>
<th>Weight (lbs)</th>
<th>Recommended Dose</th>
<th>Volume of IV Tecovirimat</th>
<th>Volume of Diluent</th>
<th>Total Volume for Infusion</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 35 kg</td>
<td>&lt; 77 lbs</td>
<td>6 mg/kg every 12 hours by IV infusion over 6 hours</td>
<td>0.6 mL/kg</td>
<td>1.2 mL/kg</td>
<td>Varies by weight</td>
</tr>
<tr>
<td>35 kg to &lt; 120 kg</td>
<td>77 to &lt; 264 lbs</td>
<td>200 mg every 12 hours by IV infusion over 6 hours</td>
<td>20 mL</td>
<td>40 mL</td>
<td>60 mL</td>
</tr>
<tr>
<td>120 kg and above</td>
<td>≥ 264 lbs</td>
<td>300 mg every 12 hours by IV infusion over 6 hours</td>
<td>30 mL</td>
<td>60 mL</td>
<td>90 mL</td>
</tr>
</tbody>
</table>

a FDA-approval of IV tecovirimat is for a 14-day treatment course of a life-threatening indication of smallpox. Patients should be switched to tecovirimat oral capsules to complete the standard 14-day treatment course as soon as oral therapy can be tolerated.

b 10 mg/mL stock solution containing 40% hydroxypropyl-β-cyclodextrin (8 g per vial) with water for injection.

c Diluent is either 0.9% (w/v) sodium chloride injection or 5% (w/v) dextrose injection solution.

d IV tecovirimat dose of 6 mg/kg for children <3 kg is allowed under this IND protocol, which differs from the FDA-approved tecovirimat package insert. Individualized dosing may need to be considered depending on the neonate or infant weight and any underlying conditions. Pediatric doses are solely based on predicted exposures from population PK simulation based on observed exposure in healthy adult subjects receiving 600 mg oral doses twice daily.
For children under 2 years of age: monitor renal function during the treatment course given the potential for drug accumulation due to renal immaturity of pediatric patients less than 2 years.

Depending on size of syringe available with syringe pump system, two separate syringes may be needed for each 6-hour administration.

Based on currently available information, the infusion should be administered over 6 hours via syringe pump. The 6-hour duration of infusion is based on how the IV formulation was evaluated, observed transient ataxia in nonhuman primates dosed over 4 hours at 30 mg/kg, and to target optimal antiviral effect. The administration via syringe pump is based on available compatibility data for the formulation. Due to the high content of the inactive ingredient hydroxypropyl-β-cyclodextrin in IV tecovirimat formulation (8 gm HP-β-CD per 200 mg tecovirimat injection vial), there is an elevated risk for potential leaching of impurities into the solution during preparation and administration when equipment other than syringes/syringe pumps are used. This has been mitigated through appropriate studies for syringe pumps. Therefore, the use of empty or prefilled infusion bags are not recommended for use with IV tecovirimat. The manufacturer recommends against the use of glass IV bottles for preparation and administration of IV tecovirimat (see SIGA’s Dear Healthcare Provider letter at [https://www.siga.com/wp-content/uploads/2022/08/NDA_Final.pdf](https://www.siga.com/wp-content/uploads/2022/08/NDA_Final.pdf)).

### 4.2.1 Duration of IV Therapy

The duration of IV tecovirimat for patients of all ages is 14 days if the patient’s condition necessitates IV administration (e.g., inability to tolerate the oral form, severity of symptoms [e.g., systemic illness], comorbidities, underlying disease, and/or other factors that may alter oral drug absorption). IV tecovirimat should only be administered while patients are unable to take oral therapy or there is a concern that oral drug absorption may be altered. Patients should be switched to the oral formulation as soon as they are able to take oral medications and/or gastrointestinal dysfunction impacting absorption has resolved. The timing of transition to oral therapy is based on the clinical judgement of the treating clinician depending on the clinical progress of the patient, and any monitoring that may be needed to ensure adequate oral drug absorption.

### 4.4 Discontinuation of Tecovirimat

At any time during treatment, a patient may voluntarily discontinue or refuse tecovirimat treatment for any reason, or treatment may be stopped or paused due to serious adverse events (SAEs), clinically significant abnormalities in laboratory values, or per the clinical judgment of the treating clinician and/or appropriate health authority.

### 4.5 Drug-Drug Interactions

Tecovirimat is a weak inducer of cytochrome P450 (CYP)3A and a weak inhibitor of CYP2C8 and CYP2C19. However, the effects are not expected to be clinically relevant for most substrates of those enzymes based on the magnitude of interactions and the duration of treatment of tecovirimat. See Table 3a for clinical recommendations for select sensitive substrates. Co-administration of tecovirimat with repaglinide may cause hypoglycemia. Monitor blood glucose and monitor for hypoglycemic symptoms during co-administration.

#### Table 3a. Significant Drug Interactions

<table>
<thead>
<tr>
<th>Concomitant Drug Class: Drug Name</th>
<th>Effect on Concentration</th>
<th>Clinical Effect/Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Blood Glucose-Lowering Agent:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Repaglinide&lt;sup&gt;b&lt;/sup&gt;</td>
<td>↑ repaglinide</td>
<td>Monitor blood glucose and monitor for hypoglycemic symptoms in patients when tecovirimat is co-administered with repaglinide</td>
</tr>
<tr>
<td>Central Nervous System Depressant:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Midazolam&lt;sup&gt;b&lt;/sup&gt;</td>
<td>↓ midazolam</td>
<td>Monitor for effectiveness of midazolam</td>
</tr>
</tbody>
</table>

<sup>a</sup> ↓ = decrease, ↑ = increase  
<sup>b</sup> These interactions have been studied in healthy adults.
Based on a drug interaction study, no clinically significant drug interactions have been observed when tecovirimat is co-administered with bupropion, flurbiprofen, or omeprazole.

While no clinical drug-drug interaction studies have been conducted between antiretroviral drugs and tecovirimat, based on FDA assessment of drug interaction study results with other drugs, no dose adjustments are needed when tecovirimat is co-administered with rilpivirine, doravirine, or maraviroc. However, Cabenuva (long-acting cabotegravir and rilpivirine kit) should not be initiated during tecovirimat treatment and for 2 weeks after completion of tecovirimat treatment (Table 3b). For more information, see: https://www.cdc.gov/mmwr/volumes/71/wr/mm7132e4.htm?s_cid=mm7132e4.

### Table 3b. Antiretroviral Drug Interactions

<table>
<thead>
<tr>
<th>Concomitant Drug Name</th>
<th>Clinical Effect/Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cabenuva (long-acting cabotegravir and rilpivirine kit)</td>
<td>Avoid initiation of Cabenuva during tecovirimat treatment and within 2 weeks post tecovirimat treatment</td>
</tr>
<tr>
<td>Rilpivirine</td>
<td>No dose adjustment needed</td>
</tr>
<tr>
<td>Doravirine</td>
<td>No dose adjustment needed</td>
</tr>
<tr>
<td>Maraviroc</td>
<td>No dose adjustment needed</td>
</tr>
</tbody>
</table>

A complete list of concomitant medications and medication history should be reviewed when starting a patient on tecovirimat treatment, and clinicians should monitor for potential drug-drug interactions accordingly. Any SAEs that occur must be reported by returning a completed MedWatch form to CDC (see Section 8.0 for required SAE reporting and definitions of AEs).

No vaccine-drug interaction studies have been performed in human subjects. Studies in mice and non-human primates have indicated that tecovirimat co-administered with live smallpox vaccine (vaccinia virus) may reduce the immune response to the vaccine [16, 17]. The clinical impact of this interaction on vaccine efficacy is unknown.

### 5.0 POSSIBLE RISKS OF TECOVIRIMAT TREATMENT

Co-administration with repaglinide may cause hypoglycemia. Monitor blood glucose and monitor for hypoglycemic symptoms during co-administration. Other risks associated with administration of tecovirimat to patients with orthopoxvirus infections are unknown. See Section 10.1 for more information on human safety, including adverse events to oral and IV tecovirimat.

**Contraindications, Warnings, and Precautions**

Given the theoretical safety concern of renal toxicity related to HP-β-CD exposure, IV tecovirimat has a labeled contraindication in patients with severe renal impairment (CrCl <30 mL/min). IV tecovirimat in patients with decreased renal function, including severe, moderate (defined as CrCl 30-49 mL/min) and mild (defined as CrCl 50-80 mL/min), should be used with caution, monitoring of renal function, and considered on a case-by-case determination by the treating clinician based on clinical judgment of the risk/benefit for the patient. Serum creatinine levels should be closely monitored and, if renal toxicity is suspected, consideration should be given to switching to oral tecovirimat as soon as feasible. See Section 6.4 for additional information.

### 6.0 SPECIAL POPULATIONS

Tecovirimat treatment may be considered for patients in the following special populations based on careful clinical assessment of individual patient’s clinical condition and weighing the serious risk of orthopoxvirus infection and potential benefit of tecovirimat with the potential risks of this product.

#### 6.1 Pregnancy

Tecovirimat has not been studied in pregnant individuals; however, reproductive development studies have been performed in mice and rabbits and no embryo-fetal abnormalities were recorded. Pregnant mice
were administered tecovirimat orally at doses up to 1,000 mg/kg/day from gestation Days 6-15 (approximately 23 times higher than human exposure at the recommended human dose). Considering the serious, and potentially deadly, risks associated with orthopoxvirus infections (e.g., vaccinia [including complications from smallpox vaccine or secondary exposure to a smallpox-vaccinee], mpox, and cowpox), the potential benefits of treatment with oral or intravenous tecovirimat may outweigh the unknown pregnancy risks associated with tecovirimat.

6.2 Lactation
No studies of tecovirimat use in nursing individuals have been conducted. Considering the serious, and potentially deadly, risks associated with orthopoxvirus infections (e.g., variola, vaccinia [including complications from smallpox vaccine or secondary exposure to a replication-competent smallpox-vaccinee], mpox, and cowpox), the potential benefits of treatment with oral or intravenous tecovirimat may outweigh the unknown risks associated with tecovirimat use during lactation. Because of the potential for virus transmission through direct contact with the breastfed infant, breastfeeding is not recommended while the nursing individual has active lesions. A lactating individual may consider interrupting breastfeeding and may consider pumping and discarding breast milk during treatment.

In lactating mice given oral tecovirimat doses up to 1,000 mg/kg/day, mean tecovirimat milk to plasma ratios up to approximately 0.8 were observed at 6 and 24 hours post-dose when administered orally on lactation Day 10 or 11.

6.3 Pediatric Population
As in adults, the effectiveness of tecovirimat in pediatric patients is based solely on efficacy studies in animal models of orthopoxvirus disease. As exposure of healthy pediatric subjects to tecovirimat with no potential for direct clinical benefit is not ethical, PK simulation was used to derive dosing regimens that are predicted to provide pediatric patients with exposures comparable to the observed exposure in adults receiving 600 mg twice daily. The dosage for pediatric patients is based on weight. Considering the serious, and potentially deadly, risks associated with orthopoxvirus infections (e.g., vaccinia [including complications from smallpox vaccine or secondary exposure to a smallpox-vaccinee], mpox, and cowpox), the potential benefits of treatment with oral or intravenous tecovirimat may outweigh the unknown pediatric risks associated with tecovirimat.

IV tecovirimat
There are limited data regarding the use of HP-β-CD, an ingredient in IV tecovirimat, in pediatric patients < 2 years of age. Given the potential for drug accumulation due to renal immaturity in pediatric patients less than 2 years, monitoring of renal function during the treatment course is recommended.

6.4 Patients with Renal Impairment
Tecovirimat capsules
No dosage adjustment is required for patients with mild, moderate, or severe renal impairment or patients with end stage renal disease (ESRD) requiring hemodialysis [see Clinical Pharmacology (12.3)].

IV tecovirimat
IV tecovirimat has a labeled contraindication in patients with severe renal impairment (CrCl <30 mL/min) because of the potential risk of HP-β-CD accumulation, which is removed by glomerular filtration. Renal function and laboratory values should be monitored during IV tecovirimat treatment, especially in patients with decreased renal function.

7.0 CLINICAL ASSESSMENT AND MONITORING OF PATIENTS
Upon presentation, the patient should be thoroughly assessed per clinician’s judgement to determine if tecovirimat treatment is appropriate. This may include a medical history, review of concomitant medications and any prior tecovirimat treatment, and a physical examination with vital signs (e.g., weight,
blood pressure, pulse, respiratory rate, temperature). Clinical assessment and monitoring can be conducted in person or by telemedicine, whichever is feasible.

**Tecovirimat (TPOXX) IND Registry and Access to the Secure Electronic Patient Intake and Clinical Outcome Forms**

- Beginning on October 28, 2022, all providers must register as participating providers under the CDC-held EA-IND protocol by completing the **Tecovirimat (TPOXX) IND Online Registry for Providers/Facilities**. The registry includes an online Form FDA 1572. Providers should register prior to providing tecovirimat treatment to the extent feasible and no later than 7 calendar days of first prescribing or administering tecovirimat. A **TPOXX IND registry factsheet** was also posted that provides step-by-step instructions on completing the Tecovirimat (TPOXX) IND Online Registry for Providers/Facilities.
- Also starting on October 28, 2022, the required **Patient Intake and Clinical Outcome forms** are available electronically for completion and submission to CDC for each patient treated with tecovirimat through the **Tecovirimat (TPOXX) IND Online Registry for Providers/Facilities**. Because these forms involve providing personally identifiable information, they are not publicly posted. Rather, access to the secure externally facing electronic forms will be sent via email to registered providers. Please be informed that system-generated emails containing a **tokenized link** for each electronic form (e.g., Patient Intake Form and Clinical Outcome Form) will be sent to registered provider’s email address from “CDC TPOXX IND <noreplydcipher@cdc.gov>.”
- The providers who have submitted Form FDA 1572 and/or TPOXX IND Patient Intake or Clinical Outcome forms to CDC prior to the online registry are considered participating providers and do not need to register. These providers with valid email addresses included in the returned forms to CDC received emails containing a **tokenized link** for each electronic form in late October 2022. For details, please refer to Information for Healthcare Providers: Tecovirimat (TPOXX) for Treatment of Mpox | Mpox | Poxvirus | CDC.

Treating clinicians or their designees will be responsible for patient assessment, monitoring, and reporting information to CDC. The following are required to be completed, retained, and/or returned to CDC:

- **Obtain Informed Consent** – prior to initiating tecovirimat treatment; provide a copy to the patient and retain a copy at the treating facility/institution. A copy does NOT need to be returned to CDC. Only if the signed informed consent forms cannot be maintained at the treating facility/institution and there are no other suitable means to store/retain the documents, then they may be sent to CDC within 7 calendar days of tecovirimat initiation.
- **Register online** (required for new providers only) – All new providers must register as participating providers by completing the **Tecovirimat (TPOXX) IND Online Registry for Providers/Facilities** prior to providing tecovirimat treatment to the extent feasible and no later than 7 calendar days of first prescribing or administering tecovirimat.
- **Complete** the electronic **Patient Intake form - this must** be completed for each patient who is prescribed and treated with tecovirimat. Complete the electronic form as soon as feasible and no later than 7 calendar days of prescribing or initiating therapy. For patients who are being re-initiated on tecovirimat treatment after completing a prior tecovirimat treatment course (e.g., relapse of infection, recrudescence), a new Patient Intake form should be completed and returned to CDC. The relevant information may include:
  - Medical history, baseline signs/symptoms, vital signs, concomitant medications
  - Relevant clinical laboratory results if performed per treating clinician’s clinical judgment depending on patient’s underlying condition
- **Complete** the electronic **Clinical Outcome Form**: Patient follow-up should be conducted within 3–7 calendar days of completing tecovirimat treatment and submit the electronic Clinical Outcome form. The relevant information may include:
- Tecovirimat treatment information, patient’s progress, lesion status, and relevant clinical laboratory information if performed per treating clinician’s clinical judgement on patient’s condition

Providers must complete and return the Clinical Outcome form electronically, especially for patients who:
- Received extended duration of tecovirimat beyond initial 14-day treatment or received repeat courses of tecovirimat after completing a prior treatment course
- Are pregnant
- Are less than 18 years of age
- Were hospitalized
- Discontinued tecovirimat treatment prior to the standard 14-day course

During an outbreak response, the Clinical Outcome Form may be made optional to lessen the reporting burden on providers depending on specific circumstances, extent, and size of the outbreak. If the Clinical Outcome Form is made optional during an outbreak, CDC will communicate this accordingly on its website and through webinars and listserv notifications.

- **Adverse Event Reporting** – Report serious or life-threatening AEs (e.g., anaphylaxis, hospitalization/prolonged hospitalization, death; see below the definition of SAE), selected AEs of interest (see below the list) and/or medication errors associated with tecovirimat to CDC. Report SAEs and/or selected AEs of interest (defined below) by:
  - Completing a fillable-PDF MedWatch Form and returning to CDC via email (regaffairs@cdc.gov) within 72 hours of awareness or sooner if possible. A fillable-PDF MedWatch Form can also be downloaded from MedWatch Forms for FDA Safety Reporting | FDA
  - SAE is defined as death, life-threatening AE, inpatient hospitalization, or prolongation of existing hospitalization, persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions; congenital anomaly/birth defect; an important medical event that based on appropriate medical judgement may jeopardize the patient and may require medical or surgical intervention to prevent one of the aforementioned outcomes.
  - Selected AEs of interest include: seizure, tremor and/or tingling sensation, purpura, renal function abnormalities, or hepatic function abnormalities

- **Optional Laboratory Testing**
Under this IND program, the following laboratory testing are **not required** and optional per treating clinician’s decision:

  - Perform clinical laboratory testing (e.g., hematology, chemistry, urinalysis) per treating clinician’s clinical judgment depending on the underlying clinical conditions to monitor the safety of tecovirimat treatment (e.g., baseline, during, or post treatment) as appropriate.

  - Optional lesion specimens may be sent to CDC for tecovirimat-treated patients with persistent lesions during tecovirimat treatment and/or when any new lesions develop after ≥ 7 days of tecovirimat treatment to assess for development of antiviral resistance mutations. The resistance testing at CDC is available if there is lack of clinical and/or virologic response to tecovirimat (clinical worsening, not resolving lesion, new lesions), giving clinical suspicion for potential resistance to tecovirimat.
    - See Attachment 4 (Optional Lesion Specimens to CDC for Resistance Testing) for collection and shipping instructions. The resistance testing at CDC is available if there is clinical suspicion of lower effectiveness (clinical worsening, not resolving lesion, new lesions).
Please be informed that patient-specific results cannot be reported back to providers or patients to guide individual patient management as these tests are not certified under the Clinical Laboratory Improvement Amendments (CLIA) regulations. However, treating clinicians are encouraged to send specimens to CDC when clinical suspicions for resistance are present for public health surveillance purpose. This is important for continued monitoring by CDC for potential emergence of antiviral resistance. Tecovirimat resistance has been detected in a small number of patients with advanced HIV who received tecovirimat treatment for weeks to months. Of more than 5,000 specimens sent to CDC for testing during the 2022 mpox outbreak, less than 0.5% specimens have been found to develop resistance per available information as of February 2023 [18-21].

- Serology testing at CDC is available if requested by the treating clinicians. Testing may be considered if there are concerns that the patient may not develop a normal immune response. Samples collected at baseline may be important for later interpretation.

- If feasible to participate in optional plasma pharmacokinetic sample(s) collection for testing at a designated laboratory (Alturas Analytics) to help inform drug exposure, see Attachment 5 for instructions. Please ensure notifying CDC (regaffairs@cdc.gov) by email if PK samples are sent to Alturas to help match the patient information submitted to CDC under the IND with the patient PK samples sent to Alturas. Clinicians may consider prioritizing PK sample collection from certain patients (e.g., critically ill patients, those with concerns for altered drug absorption, pediatric, pregnant) whose oral tecovirimat drug exposure levels may be subtherapeutic. Patient-specific results cannot be reported back to the providers or patients for directly informing individual patient management as the PK test is not CLIA-certified. However, aggregated results when accumulated and available would inform drug exposure levels of patients with orthopoxvirus infections, especially given the lack of tecovirimat PK data in patients with poxvirus disease.

### Table 4. Summary of Clinical Assessment and Monitoring Parameters

<table>
<thead>
<tr>
<th>Parameters</th>
<th>Days</th>
<th>Pre-Tecovirimat Treatment a</th>
<th>Post Completion of Tecovirimat Treatment b</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Patient Intake Form (Attachment 2-A)</td>
<td>Clinical Outcome Form (Attachment 2-B)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Prior to first dose of Tecovirimat (≤ 24 hours)</td>
<td>Outpatients: 3–7 Days after treatment completion</td>
</tr>
<tr>
<td>Sign Informed Consent</td>
<td></td>
<td>x</td>
<td>N/A</td>
</tr>
<tr>
<td>Inclusion/Exclusion Criteria</td>
<td></td>
<td>x</td>
<td>N/A</td>
</tr>
<tr>
<td>Baseline clinical assessment</td>
<td></td>
<td>x</td>
<td>N/A</td>
</tr>
<tr>
<td>Clinical progress</td>
<td></td>
<td>N/A</td>
<td>x</td>
</tr>
<tr>
<td>Serious Adverse Events b</td>
<td></td>
<td>N/A</td>
<td>Report if SAEs, select AEs of interest, and/or medication errors occur</td>
</tr>
<tr>
<td>Hematology, chemistry, urinalysis</td>
<td></td>
<td>Optional</td>
<td>Optional</td>
</tr>
<tr>
<td>Lesion samples</td>
<td></td>
<td>Optional</td>
<td>Optional (for any new lesions post-treatment)</td>
</tr>
<tr>
<td>PK samples</td>
<td></td>
<td>Optional</td>
<td>Optional</td>
</tr>
</tbody>
</table>

*For outpatients, assessment may be conducted via telemedicine.

*SAEs must be reported to CDC within 72 hours of awareness or sooner if possible.
8.0 RECORDING AND REPORTING SERIOUS ADVERSE EVENTS

8.1 Definitions (21 CFR 312.32)
An **ADVERSE EVENT** (AE) is any untoward medical occurrence associated with the use of tecovirimat in humans, whether or not considered related to tecovirimat. It can be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of tecovirimat, without any judgment about causality.

A **SUSPECTED ADVERSE REACTION** is any AE for which there is a reasonable possibility that tecovirimat caused the AE. It is a subset of all AEs for which there is a reasonable possibility that tecovirimat caused the event. “Reasonable possibility” means there is evidence to suggest a causal relationship between tecovirimat and the AE. “Suspected adverse reaction” implies a lesser degree of certainty about causality than “adverse reaction.”

An **ADVERSE REACTION** is any AE caused by tecovirimat. Adverse reactions are a subset of all suspected adverse reactions for which there is a reason to conclude that tecovirimat caused the event.

**UNEXPECTED**: An AE is considered “unexpected” if it is not listed in this protocol or Package Insert, or is not listed at the specificity or severity observed.

**SERIOUS**: An AE or suspected adverse reaction is considered “serious” if in the view of either the treating clinician or CDC, it results in any of the following outcomes:
- death
- a life-threatening AE
- inpatient hospitalization or prolongation of existing hospitalization
- a persistent or significant incapacity or substantial disruption of the ability to conduct normal life functions
- a congenital anomaly/birth defect

**NOTE**: Important medical events that may not result in death, be life-threatening, or require hospitalization may be considered serious when, based upon appropriate medical judgment, they may jeopardize the patient and may require medical or surgical intervention to prevent one of the outcomes previously listed.

**LIFE-THREATENING**: An AE or suspected adverse reaction is considered “life-threatening” if, in the view of either the treating clinician or CDC, its occurrence places the patient at immediate risk of death. It does not include an AE or suspected adverse reaction that, had it occurred in a more severe form, might have caused a death.

8.2 Treating Clinician Reporting Requirements to CDC
All SAEs and selected AEs of interest must be reported. These include all SAEs and selected AEs of interest that the patient reports spontaneously, those the clinician observes, and those the clinician elicits in response to open-ended questions. All SAEs and selected AEs of interest, whether or not the treating clinician considers the event to be drug-related, must be reported to CDC within 72 hours of awareness or sooner if possible (see Section 7.0).

8.3 CDC Reporting Requirements to FDA and CDC Institutional Review Board (IRB)
CDC will review all SAEs and report serious, unexpected suspected adverse reactions to FDA within 15 calendar days of initial receipt or after determining that the information qualifies for reporting under 21 CFR 312.32I(1).

In cases of unexpected suspected adverse reactions that are fatal or life-threatening (serious), CDC will report to FDA as soon as possible, but no later than 7 calendar days after initial receipt of the information (21 CFR 312.32(c)(2)).
All three (3) of the definitions contained in the requirement must be met for expedited reporting to FDA:
1. Serious,
2. Unexpected, and
3. Suspected Adverse Reaction.

CDC will report all serious and unexpected suspected adverse reactions and incidents to CDC IRB according to CDC IRB’s policy and procedures.

AEs that are voluntarily reported by providers to CDC that do not meet the requirements for expedited reporting to FDA will be submitted under the IND in Annual Reports.

9.0 REGULATORY AND ADMINISTRATIVE REQUIREMENTS
CDC, the sponsor of the IND, and all licensed healthcare providers who request and receive tecovirimat under this IND protocol will abide by the Code of Federal Regulations (in particular, 21 CFR Parts 50, 56, and 312). The IND protocol is subject to FDA’s review and authorization as well as review and approval by an Institutional Review Board (IRB). CDC IRB serves as the central IRB for review and approval of this tecovirimat IND protocol, and has determined it non-research (i.e., does not constitute human subjects research per 45 CFR 46.102(l)). Therefore, participating sites may use CDC IRB’s approval of this protocol that meets FDA’s requirements regarding IRB review per 21 CFR Parts 50 and 56.

Any change or modification to the IND protocol that affects purpose, procedures, or significant data or administrative aspects of the program will require a formal amendment. Such amendments will be submitted to FDA for review and approved by the CDC IRB prior to implementation. Revised IND protocol and/or procedural modifications will be communicated by CDC to the clinicians and medical facilities participating in the tecovirimat treatment.

Data Management and Handling
IND case report forms (Attachment 2), laboratory results, visit summaries, hospital discharge summaries, medical records, etc., may be used as source documents. The information obtained through the case report forms of this IND protocol and additional supplemental information provided by treating clinicians to CDC will be maintained by the CDC. Any analysis of data contents will be conducted without individual identifiers. The information gathered under this expanded access IND program and any analysis generated will be reported to the FDA as part of the annual report for this IND. Data from case report forms and other related information collected under this IND may also be provided to SIGA Technologies, Inc. and the Department of Health and Human Services/Biomedical Advanced Research and Development Authority (HHS/BARDA). Information about specific treating clinicians (i.e., names, CVs, or Form FDA 1572) and/or hospitals/sites may be shared with FDA, and local public health jurisdictions, and the manufacturer. Any information pertaining to treating clinicians and/or participating sites that are provided to the manufacturer is limited to use in the manufacturer’s discussions with health authorities concerning this CDC-sponsored IND program.

Informed Consent
Informed consent in compliance with 21 CFR 50 must be obtained via the enclosed informed consent/permission form (Attachment 1) from the patient, including adolescents, deemed as mature or emancipated minors by state and/or local law who can consent for themselves, before tecovirimat is administered. If the patient is unable to give consent, consent can be obtained from a legally authorized representative (LAR).

A single consent form (Attachment 1) will be used to obtain informed consent/parental permission. Waiver of assent for children (7–11 years of age) under 21 CFR 50.55(c)(1) and for children (12–17 years of age) under 21 CFR 50.55(c)(2) was approved by the CDC IRB for all patients under this IND program.
Parental permission will be sought in accordance with 21 CFR 50.55 for children aged 12–17 years (permission of only one parent is required) with exceptions for adolescents, deemed as mature or emancipated minors by state and/or local law who can consent for themselves for medical care. The ultimate responsibility for decision-making regarding treatment with tecovirimat in minors should lie with the parent or guardian, or by the adolescents, deemed as mature or emancipated minors by state and/or local law who can consent for themselves for medical care.

For patients with limited English proficiency, if a version of the informed consent form is not available in the patient’s (LAR’s) language, the form must be translated orally by a certified interpreter. If a certified interpreter is not available, another adult who is fluent in both English and the language needed may interpret, provided the patient (parent/LAR) is comfortable sharing medical information (i.e., the reason treatment is being offered) with that person. If a facility wishes to create a written translation of the informed consent form, the CDC IRB-approved informed consent form must be translated by a certified translator and the translation must be submitted to and approved by the CDC IRB prior to use. A short form for obtaining informed consent from patients with limited English proficiency, along with a written summary of the information in the informed consent form (Attachment 1) for use with the short form are available online on CDC’s website. The same requirements for interpretation or translation additionally apply to the short form.

In the rare situation that a patient is unable to respond and make wishes known about tecovirimat treatment, no next-of-kin or legal representative is available, and the patient’s illness is life-threatening, obtaining informed consent may be deemed not feasible per 21 CFR 50.23 “Exception from general requirements.” In such situations that necessitate tecovirimat treatment, the patient’s treating clinician and a clinician who is not otherwise participating in this expanded access IND program will document the clinical determination on the last page of the informed consent form (Attachment 1). The information in the consent form should be provided to the patient or LAR at the first available opportunity. Notify CDC via email (regaffairs@cdc.gov) within 3 working days of tecovirimat initiation when the treatment determination was made based on the mentioned certification by the treating and an independent clinician.

10.0 SUMMARY OF AVAILABLE SAFETY AND EFFICACY DATA OF TECOVIRIMAT

10.1 Human Safety Data of Tecovirimat

Most Frequently Reported Adverse Reactions to Oral Tecovirimat

Based on a safety study of oral tecovirimat in 359 healthy adult subjects ages 18–79 years in a phase 3 clinical trial, the most frequently reported adverse reactions were headache and nausea. Adverse reactions that occurred in at least 2% of subjects in the tecovirimat treatment group are shown in Table 5.

Table 5. Adverse Reactions Reported in ≥ 2% of Healthy Adult Subjects Receiving at Least One Dose of Oral Tecovirimat 600 mg

<table>
<thead>
<tr>
<th></th>
<th>TPOXX 600 mg N =359 (%)</th>
<th>Placebo N = 90 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Headache</td>
<td>12</td>
<td>8</td>
</tr>
<tr>
<td>Nausea</td>
<td>5</td>
<td>4</td>
</tr>
<tr>
<td>Abdominal Pain</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>Vomiting</td>
<td>2</td>
<td>0</td>
</tr>
</tbody>
</table>

* Includes abdominal pain, abdominal pain upper, abdominal distension, abdominal discomfort, abdominal pain lower, and epigastric pain.
Adverse Reactions Leading to Discontinuation of Oral Tecovirimat

Six subjects (2%) had tecovirimat discontinued due to adverse reactions. Each of these subject’s adverse reactions (with severity) is listed below:

- Electroencephalogram change, abnormal
- Mild upset stomach, dry mouth, decreased concentration and dysphoria
- Mild nausea and fever, moderate diarrhea, severe headache
- Mild palpable purpura
- Mild nausea, fever, and chills
- Mild facial redness, facial swelling, and pruritus

Less Common Adverse Reactions to Oral Tecovirimat

Clinically significant adverse reactions that were reported in < 2% of subjects exposed to tecovirimat and at rates higher than subjects who received placebo are listed below:

- Gastrointestinal: dry mouth, chapped lips, dyspepsia, eructation, oral paresthesia
- General and administration site: pyrexia, pain, chills, malaise, thirst
- Investigations: abnormal electroencephalogram, hematocrit decreased, hemoglobin decreased, heart rate increased
- Musculoskeletal and connective tissue: arthralgia, osteoarthritis
- Nervous system: migraine, disturbance in attention, dysgeusia, paresthesia
- Psychiatric: depression, dysphoria, irritability, panic attack
- Respiratory, Thoracic and Mediastinal Disorders: oropharyngeal pain
- Skin and subcutaneous tissue: palpable purpura, rash, pruritic rash, facial redness, facial swelling and pruritus

Adverse Events to IV Tecovirimat

The most frequently reported AEs in a multiple-dose study of IV tecovirimat included infusion site pain, infusion site swelling, infusion site erythema, infusion site extravasation, and headache. Three subjects (12%) had their treatment with IV tecovirimat discontinued due to an AE for the following reasons: infusion site extravasation (moderate); infusion site extravasation (mild); infusion site swelling and pain (mild). Adverse reactions that occurred in at least 4% of subjects in the tecovirimat treatment group are in Table 6. Adverse reactions that were reported in < 4% of subjects exposed to tecovirimat and at rates higher than subjects who received placebo were: infusion site discomfort, infusion site edema, myalgia, arthritis, back pain, muscle tightness, diarrhea, photophobia, and pruritus generalized.

<table>
<thead>
<tr>
<th></th>
<th>IV Tecovirimat 600 mg N =26 (%)</th>
<th>Placebo N = 6 (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Infusion Site Pain</td>
<td>73</td>
<td>67</td>
</tr>
<tr>
<td>Infusion Site Swelling</td>
<td>39</td>
<td>67</td>
</tr>
<tr>
<td>Infusion Site Erythema</td>
<td>23</td>
<td>67</td>
</tr>
<tr>
<td>Infusion Site Extravasation</td>
<td>19</td>
<td>50</td>
</tr>
<tr>
<td>Headache</td>
<td>15</td>
<td>0</td>
</tr>
</tbody>
</table>

10.2 Clinical Use of Tecovirimat

NV-OPXV-infected Patients (2007-2021)

While tecovirimat has not been studied in human orthopoxvirus disease, tecovirimat treatment was provided under expanded access IND (EA-IND) to 7 patients in the U.S. (including one pediatric patient) prior to the 2022 multinational mpox outbreak. There were at least 5 patients outside the U.S. who received tecovirimat treatment prior to the 2022 mpox outbreak. Infections were caused by vaccinia virus (n=6), cowpox virus (4), and mpox (n=2). All 6 patients with vaccinia virus infection had also received
Vaccinia Immunoglobulin Intravenous (Human) (VIGIV) and recovered from their infection [22-26]. In addition to oral tecovirimat and VIGIV, a 28-month old child with eczema vaccinatum was also treated with cidofovir and a 20-year-old patient with progressive vaccinia was also treated with brincidofovir and topical imiquimod [22, 24]. Two patients with mpox recovered from their illness [5, 7] while two of four patients with cowpox, who both had a history of organ transplant, resulted in death from their illness.

Tecovirimat was generally well tolerated with one patient who experienced mild AEs (nausea, loss of appetite, fatigue, myalgia, and pruritus).

**Tecovirimat use during the 2022 U.S. Mpox Outbreak under the IND 116,039/CDC IRB Protocol #6402**

During the 2022 Mpox outbreak in the U.S. that emerged in mid May 2022, stockpiled tecovirimat was made available under EA-IND for treatment of mpox patients in concert with CDC’s interim clinical guidance. From May 27, 2022 through January 21, 2023, 6,832 patients were prescribed or treated with tecovirimat under the EA-IND based on returned IND Patient Intake forms (Figure 1) although this likely underrepresents the total number of tecovirimat-treated patients during the mpox outbreak given that the return of Patient Intake forms were dependent on compliance with the requirement to complete and submit the forms to CDC. Figure 2 summarizes the age and gender of tecovirimat-prescribed patients.

**Figure 1. Patients prescribed tecovirimat, by week* (N=6,832)**

![Graph showing patients prescribed tecovirimat by week.](image)

* Number of patients based on date of assessment at start of tecovirimat treatment or date of prescription/administration of tecovirimat as of 1/21/2023.

**Figure 2: Cumulative Number of Tecovirimat-prescribed Patients Reported to CDC: Age and Gender**

![Graph showing cumulative number of tecovirimat-prescribed patients by age and gender.](image)
The majority of patients (6129; 90%) were prescribed oral tecovirimat at the start of therapy. The reasons reported for initiation of tecovirimat treatment included lesions in sensitive anatomical areas (4,633; 68%), pain (2,845; 42%), and risk of severe outcome due to immunosuppression (2,107; 31%). HIV/AIDS status was documented for 3,510 (51%) patients.

The median time to tecovirimat initiation from illness onset was 7 days (IQR 4–10 days). The number of lesions reported at the start of tecovirimat treatment were: < 10 lesions for 2,774 (41%) patients; 10–100 lesions for 3,536 (52%) patients; > 100 lesions for 204 (3%) patients; and missing/unreported for 318 (5%) patients. The percent of body affected by lesions reported at the start of tecovirimat treatment were: < 10% for 958 (14%) patients; 10–24% for 958 (14%) patients; 25–49% for 412 (6%) patients; 50–74% for 268 (4%) patients; 75–100% for 278 (4%) for patients; and missing/unreported for 2,433 (36%) patients.

While the Patient Intake form was required to be completed and returned to CDC per the EA-IND protocol, the Clinical Outcome form was made optional beginning with protocol version 6.1, dated August 10, 2022, to reduce the burden of reporting. As such, fewer completed Clinical Outcome forms have been returned to CDC. Based on the optional Clinical Outcome forms received for 1,614 tecovirimat-treated patients as of January 21, 2023, the majority of patients continued or completed tecovirimat treatment as outpatients (1,430; 88.6%) while 90 patients (5.6%) were hospitalized after tecovirimat initiation with 7 patients (0.5%) receiving intensive care. Among patients with clinical status reported during the 14-day treatment course and/or within 3–7 days after completing the treatment course, 975 (60%) patients were reported as recovered with no sequelae, 162 (10%) reported as recovered with sequelae, 276 (17%) reported as not recovered, and 201 (12%) patients had missing information regarding recovery status.

There were 127 AEs in 76 tecovirimat-treated patients and deaths in 28 tecovirimat-treated patients reported to CDC during the mpox response as of January 21, 2023. Reported AEs included: elevated liver enzymes, headache, pruritis, urticaria, fatigue, fever, acute renal dysfunction, tremor, seizure, paresthesia, dizziness, headache, fatigue, fever, edema, anaphylaxis, edema, and thrombocytopenia. Passively reported AEs from a population of uncertain size is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The 28 deaths reported in tecovirimat-treated adult patients were assessed as complications from severe mpox infection compounded by AIDS, co-infections, and/or other clinically relevant conditions.

**10.3 Tecovirimat Efficacy in Animals**

The effectiveness of tecovirimat for treatment of smallpox disease has not been determined in humans because adequate and well-controlled field trials have not been feasible and inducing smallpox disease in humans to study the drug’s efficacy is not ethical. Therefore, the effectiveness of tecovirimat for treatment of smallpox disease was established based on results of adequate and well-controlled animal efficacy studies of non-human primates and rabbits infected with non-variola orthopoxviruses. Survival rates observed in the animal studies may not be predictive of survival rates in clinical practice.

Efficacy studies were conducted in cynomolgus macaques infected with mpox virus and New Zealand white (NZW) rabbits infected with rabbitpox virus. The primary efficacy endpoint for these studies was survival. Treatment with oral tecovirimat given at Day 4 and 5 post-challenge for 14 days resulted in statistically significant improvement in survival relative to placebo, except when given to cynomolgus macaques starting at Day 6 post-challenge. See the Package Insert for more information.
10.4 Pharmacokinetics Data
A comparison of tecovirimat exposures achieved in healthy human subjects to those observed in animal models of orthopoxvirus infection (non-human primates and rabbits infected with mpox virus and rabbitpox virus, respectively) in therapeutic efficacy studies support the dosage regimen of 600 mg twice daily for treatment of smallpox disease in humans. Overall, the PK profiles of tecovirimat and its metabolites following a single oral dose and single, 6-hour IV infusion were similar in animal and human studies [16, 28]. For both oral and IV routes of administrations, accumulation is observed after repeated administration, and steady-state is achieved within 6 days. Refer to the Package Insert for PK parameters of tecovirimat.

11.0 REFERENCES